STX-1150 A clinical-stage, single-dose epigenetic silencing therapy targeting PCSK9 to produce durable LDL cholesterol reduction without permanently changing DNA.
Visit productCosigns Received
Be the first Cosign
Put your name behind STX-1150.
Add it to your Products I use list and share why you use it.